Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 3
Author: ICICI Direct

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	19 Sep 2025	Dr. Reddy's Labs	Consensus Share Price Target	1322.70	1285.13	-	-2.84	hold	pdf Detailed Estimates
	29 Jul 2024	Dr. Reddy's Labs	ICICI Direct Reco Target	1322.70	7220.00	6840.05 (-80.66%)	Pre-Bonus/ Split	Hold	pdf post cache	Broker Report Dr Reddy's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	29 Jul 2024	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1322.70	6000.00	6840.05 (-80.66%)	Pre-Bonus/ Split	Sell	pdf post cache	Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2024	Dr. Reddy's Labs	ICICI Securities Limited Reco Target	1322.70	6350.00	6878.65 (-80.77%)	Pre-Bonus/ Split	Sell	pdf post cache	Broker Report Surging dependency on gRevlimid ICICI Securities Limited Higher gRevlimid sales, in our view, formed the premise for Dr. Reddy’s Laboratories’ (DRL) Q1FY25 beat. US sales soared 20.3% YoY to USD 462mn riding on market share gains in existing products. pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2024	Dr. Reddy's Labs	Geojit BNP Paribas Target	1322.70	6338.00	5872.75 (-77.48%)	Target met	Hold	pdf post cache	Broker Report DR. REDDY'S LABORATARIES Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	09 May 2024	Dr. Reddy's Labs	BOB Capital Markets Ltd.	1322.70	5900.00	5877.35 (-77.49%)	Target met	Hold	pdf post cache	Broker Report Dr Reddy's Labs (HOLD): Driven by North America; India continues to underperform BOB Capital Markets Ltd. DRRD reported largely in-line revenue/EBITDA, but higher tax aided in PAT beat pdf Copy Link Share on Share on Share on Share on Alert
	08 May 2024	Dr. Reddy's Labs	SMC online	1322.70		6257.60 (-78.86%)	Pre-Bonus/ Split	Results Update	pdf post cache	Broker Report Dr. Reddy Laboratories SMC online pdf Copy Link Share on Share on Share on Share on Alert
	08 May 2024	Dr. Reddy's Labs	Prabhudas Lilladhar Target	1322.70	5700.00	6056.35 (-78.16%)	Target met	Sell	pdf post cache	Broker Report DR REDDY'S LABS Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	08 May 2024	Dr. Reddy's Labs	Axis Direct	1322.70	6000.00	6056.35 (-78.16%)	Target met	Hold	pdf post cache	Broker Report Result Update:Dr Reddys Labs Axis Direct We have HOLD on the stock. pdf Copy Link Share on Share on Share on Share on Alert
	07 May 2024	Dr. Reddy's Labs	Motilal Oswal Target	1322.70	6070.00	6257.60 (-78.86%)	Target met	Neutral	pdf post cache	Broker Report US/India drive earnings growth Motilal Oswal Dr. Reddy’s Lab (DRRD) delivered 4QFY24 revenue in line with our estimate. However, EBITDA was lower than expected due to higher SGA expenses and R&D spending. In addition to US generics/branded generics segments, DRRD is enhancing its offering through JVs/partnerships/acquisitions in nutraceuticals, vaccine, women’s health and dietary supplement space. pdf Copy Link Share on Share on Share on Share on Alert
	01 Apr 2024	Dr. Reddy's Labs	Sharekhan Target	1322.70	6537.00	6237.55 (-78.79%)	Target met	Buy	pdf post cache	Broker Report Dr Reddys Labs Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
more loading

29.68% Gain from 52W Low

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1278.56. The consensus estimate represents a downside of -3.34% from the last price of 1322.70. View 18 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Dr Reddy's Laboratories

DR REDDY'S LABS

Surging dependency on gRevlimid

DR. REDDY'S LABORATARIES

Dr Reddy's Labs (HOLD): Driven by North America; India continues to underperform

Dr. Reddy Laboratories

DR REDDY'S LABS

Result Update:Dr Reddys Labs

US/India drive earnings growth

Dr Reddys Labs

Advisor Screeners